JBIO (Jade Biosciences) Total Equity: $296.46 Mil (As of Mar. 2026)


JBIO Jade Biosciences Inc JBIO
12 GF Score
Price $22.49
! 1 Warning Sign
View Full Analysis

What is Jade Biosciences Total Equity?

Jade Biosciences JBIO -0.22% 12 Total Equity is $296.46 Mil as of Mar. 2026. GuruFocus rates JBIO with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Jade Biosciences's total equity for the quarter that ended in Mar. 2026 was $296.46 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Jade Biosciences Total Equity Historical Data

* Premium members only.

The historical data trend for Jade Biosciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jade Biosciences Total Equity Chart

Jade Biosciences Annual Data
Trend Dec24 Dec25
Total Equity
-46.80 332.52

Jade Biosciences Quarterly Data
Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial 0.00 201.56 179.35 332.52 296.46
JBIO
12GF Score
Jade Biosciences Inc JBIO
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jade Biosciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Jade Biosciences's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=349.781-17.263
=332.52

Jade Biosciences's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=319.433-22.971
=296.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $296.46 Mil mean?
Jade Biosciences (JBIO) has a Total Equity of $296.46 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Jade Biosciences and its competitors.
Is Jade Biosciences' Total Equity too high?
Jade Biosciences' current Total Equity is $296.46 Mil. Overall, Jade Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Jade Biosciences' Total Equity compare to AVLN and ARDX?
Jade Biosciences' Total Equity of $296.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Jade Biosciences and its competitors. Jade Biosciences's current Total Equity is $296.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jade Biosciences stock overvalued right now?
Jade Biosciences (JBIO) has a current Total Equity of $296.46 Mil. The current Total Equity is $296.46 Mil. Jade Biosciences' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Jade Biosciences (JBIO), the current Total Equity is $296.46 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jade Biosciences Business Description

Address 221 Crescent Street, Building 23, Suite 105, Waltham, MA, USA, 02453
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
12GF Score

Get the complete analysis for JBIO

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.49
Price